Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology?

Abstract

Study Type – Diagnostic (exploratory cohort) Level of Evidence 2b OBJECTIVE To evaluate whether Raman molecular imaging (RMI, which combines digital imaging and analytical spectroscopy to evaluate the biochemical composition of interrogated material) can be used to identify biochemical differences in patients with Gleason 7 prostate cancer who progress to metastatic disease and die from prostate cancer. PATIENTS AND METHODS We identified 38 patients who had a radical prostatectomy for Gleason 7 adenocarcinoma of the prostate. Half progressed to metastatic disease and half had no evidence of disease after treatment. Patients were matched for preoperative prostate‐specific antigen level, surgical margin status, pathological stage, tumour volume, age at surgery, year of surgery and DNA ploidy. Sequential 5 µm sections were obtained from paraffin‐embedded tissue and one genitourinary pathologist selected areas of tumour for study. Principal component analysis was used to investigate the correlation between spectral response and clinical outcome. RESULTS The analysis was able to distinguish between those with progressive disease and those with no evidence of disease, most notably within the Gleason 3 regions when evaluating the epithelium and stroma as separate histological elements. A two‐sample t‐test gave P < 0.01 for both the Gleason 3 and 4 epithelium and stroma classes. CONCLUSIONS RMI is a novel technique that shows promise for identifying patients at risk of progression by visualizing molecular information not seen using other current methods. In Gleason 7 disease, RMI shows distinctive chemical differences in patients who progress to metastatic disease in both Gleason pattern 3 and 4 regions. This preliminary work lays the foundation for the further study of RMI for evaluating prostate tissue.

Endothelium in Spots – High-Content Imaging of Lipid Rafts Clusters in db/db Mice

“…Raman imaging is an emerging tool in medical diagnostics and has been already applied in the study of various pathologies [22]–[25], [33]–[35]. The db/db mice represent a genetically-modified model (leptin receptor–deficient mice) of T2DM [32].…”

Discrimination of Basal Cell Carcinoma and Melanoma from Normal Skin Biopsies in Vitro Through Raman Spectroscopy and Principal Component Analysis

“…22,27,[31][32][33][34] In skin, our previous work revealed that PCA could successfully discriminate BCC from N with sensitivity and specificity of *96% and 92%, respectively, 27 using Mahalanobis distance as a discriminator.…”

“…PCA has been applied with great success in the analysis of biological samples, being an important part of the spectral models, which detect alterations that occur after changes in the biochemistry of biological tissues. 22,27,[31][32][33][34] Within a set of spectral data, many different variations (such as differences in constituents, instrument variations, and sample handling) typically make up a particular spectrum. With several changes occurring at the same time, however, only a few independent variables account for all spectral differences, normally attributed to differences in the constitution of the samples.…”

Label-free identification and characterization of living human primary and secondary tumour cells

“…When the scattered light is passed through a spectrometer, a spectrum of peaks occurs at characteristic frequency shifts which correspond to the vibrational bonds. 20 Finally, Raman spectroscopy has distinguished between benign, primary and secondary malignancies in lymph nodes from a variety of patients. The technique is applicable to individual living cells 7,8 by focussing the laser within a microscope, and the Raman spectrum can be considered as a biochemical fingerprint of the cell.…”